Filtered By:
Condition: Bleeding
Education: Academia

This page shows you your search results in order of relevance. This is page number 6.

Order by Relevance | Date

Total 422 results found since Jan 2013.

Impact of Sex on Comparative Outcomes of Radial Versus Femoral Access in Patients With Acute Coronary Syndromes Undergoing Invasive Management: Data From the Randomized MATRIX-Access Trial
Conclusions Women showed a higher risk of severe bleeding and access site complications, and radial access was an effective method to reduce these complications as well as composite ischemic and ischemic or bleeding endpoints.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - January 1, 2018 Category: Cardiology Authors: Gargiulo, G., Ariotti, S., Vranckx, P., Leonardi, S., Frigoli, E., Ciociano, N., Tumscitz, C., Tomassini, F., Calabro, P., Garducci, S., Crimi, G., Ando, G., Ferrario, M., Limbruno, U., Cortese, B., Sganzerla, P., Lupi, A., Russo, F., Garbo, R., Ausiello, Tags: Focus on Cardiovascular Outcomes Among Women Source Type: research

Treatment of Aortic Stenosis With a Self-Expanding, Resheathable Transcatheter Valve: One-Year Results of the International Multicenter Portico Transcatheter Aortic Valve Implantation System Study Structural Heart Disease
Conclusions— The Portico TAVI system is safe and effective at 1 year, yielding low mortality and stroke rates in high-risk patients with severe AS. Clinical Trial Registration— URL: https://www.clinicaltrials.gov. Unique identifier: NCT01493284.
Source: Circulation: Cardiovascular Interventions - February 14, 2018 Category: Cardiology Authors: Linke, A., Holzhey, D., Mollmann, H., Manoharan, G., Schafer, U., Frerker, C., Worthley, S. G., van Boven, A. J., Redwood, S., Kovac, J., Butter, C., Sondergaard, L., Lauten, A., Schymik, G., Walther, T. Tags: Aortic Valve Replacement/Transcatheter Aortic Valve Implantation Structural Heart Disease Source Type: research

Oral anti-Xa anticoagulation after Trans-Aortic Valve Implantation for Aortic Stenosis: The randomized ATLANTIS trial
Conclusions ATLANTIS tests the superiority of an apixaban-based strategy versus the recommended standard of care strategy to reduce the risk of post-TAVR thromboembolic and bleeding complications in an all comer population.
Source: American Heart Journal - March 10, 2018 Category: Cardiology Source Type: research

6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial
Publication date: Available online 12 March 2018 Source:The Lancet Author(s): Joo-Yong Hahn, Young Bin Song, Ju-Hyeon Oh, Deok-Kyu Cho, Jin Bae Lee, Joon-Hyung Doh, Sang-Hyun Kim, Jin-Ok Jeong, Jang-Ho Bae, Byung-Ok Kim, Jang Hyun Cho, Il-Woo Suh, Doo-il Kim, Hoon-Ki Park, Jong-Seon Park, Woong Gil Choi, Wang Soo Lee, Jihoon Kim, Ki Hong Choi, Taek Kyu Park, Joo Myung Lee, Jeong Hoon Yang, Jin-Ho Choi, Seung-Hyuk Choi, Hyeon-Cheol Gwon Background Current guidelines recommend dual antiplatelet therapy (DAPT) of aspirin plus a P2Y12 inhibitor for at least 12 months after implantation of drug-eluting stents (DES) in patients...
Source: The Lancet - March 13, 2018 Category: General Medicine Source Type: research

Feasibility and Outcomes of Transcatheter Aortic Valve Implantation Using the Left Axillary Artery as Primary Access Site
ConclusionsThis is the first study reporting outcome after transcatheter aortic valve implantation using the LAA as default access. We conclude that it is highly feasible and safe with low rates of major vascular complications, bleeding, and stroke.Visual Abstract
Source: The Annals of Thoracic Surgery - January 26, 2019 Category: Cardiovascular & Thoracic Surgery Source Type: research

Discriminative Ability of CHA2DS2-VASc and HAS-BLED Score in Whites and Non-Whites
The CHA2DS2-VASc and HAS-BLED scoring systems are used in patients with atrial fibrillation (AF) to estimate risk of stroke and bleeding, respectively. Both were developed in minimally diverse European populations and these scores have not yet been extensively studied in US whites and non-whites. In a retrospective cohort study, we included patients with AF who received inpatient or outpatient care in a large integrated academic health system from 2011 to 2017. Cox proportional hazards were used to analyze associations between stroke and CHA2DS2-VASc score in AF patients not prescribed anticoagulation and between incident ...
Source: The American Journal of Cardiology - March 18, 2019 Category: Cardiology Authors: Sarah M Schwartz, Yacob G Tedla, Philip Greenland, Ajay Yadlapati, Rod Passman Source Type: research

Discriminative Ability of CHA2DS2-VASc and HAS-BLED Score in Whites and Nonwhites
The CHA2DS2-VASc and HAS-BLED scoring systems are used in patients with atrial fibrillation (AF) to estimate risk of stroke and bleeding, respectively. Both were developed in minimally diverse European populations and these scores have not yet been extensively studied in US whites and nonwhites. In a retrospective cohort study, we included patients with AF who received inpatient or outpatient care in a large integrated academic health system from 2011 to 2017. Cox proportional hazards were used to analyze associations between stroke and CHA2DS2-VASc score in AF patients not prescribed anticoagulation and between incident b...
Source: The American Journal of Cardiology - March 18, 2019 Category: Cardiology Authors: Sarah M. Schwartz, Yacob G. Tedla, Philip Greenland, Ajay Yadlapati, Rod S. Passman Source Type: research

Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System
Conclusion: Our findings describe the most reported risk factors for preventability of oral anticoagulant-induced bleedings. These factors may be useful for targeting interventions to improve pharmacovigilance activities in our regional territory and to reduce the burden of medication errors and inappropriate prescription. Introduction Oral anticoagulant therapy is widely used for the prevention of stroke and systemic embolism in patients with atrial fibrillation, or for the prevention and treatment of deep vein thrombosis and pulmonary embolism (Raj et al., 1994; Monaco et al., 2017). Oral anticoagulants can be di...
Source: Frontiers in Pharmacology - April 29, 2019 Category: Drugs & Pharmacology Source Type: research

The dawn of aspirin free strategy after short term dual antiplatelet for percutaneous coronary intervention: meta-analysis of randomized controlled trials
AbstractThere is still a debate about the safety and efficacy of an aspirin free strategy after percutaneous coronary intervention (PCI). Hence, we performed a meta-analysis comparing aspirin free strategy to dual antiplatlets therapy (DAPT). Randomized trials (RCTs) comparing aspirin free strategy to DAPT in patients who received PCI were included. The primary outcome of interest was bleeding, defined per the Bleeding Academic Research Consortium (BARC). Secondary outcomes included major adverse cardiovascular and cerebrovascular events (MACE); defined as all-cause mortality, myocardial infarction or stroke, the individua...
Source: Journal of Thrombosis and Thrombolysis - November 20, 2019 Category: Hematology Source Type: research

Is oral anticoagulation effective in preventing transcatheter aortic valve implantation failure? A propensity matched analysis of the Italian Transcatheter balloon-Expandable valve Registry study
Conclusion After TAVI with Edwards Sapien valve OAT did not reduce the incidence of valve dysfunction and stroke but was responsible for mortality and bleeding increases.
Source: Journal of Cardiovascular Medicine - December 27, 2019 Category: Cardiology Tags: Research articles: Interventional cardiology Source Type: research

Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS
Conclusion  Among patients with or without NSTE-ACS who have completed an initial 3-month course of DAPT following PCI with DES, ticagrelor monotherapy reduced clinically meaningful bleeding events without increasing ischaemic risk as compared with ticagrelor plus aspirin. The benefits of ticagrelor monotherapy with respect to bleeding events were more pronounced in patients with NSTE-ACS.Trial registrationClinicaltrials.gov identifier: NCT02270242.
Source: European Heart Journal - October 20, 2020 Category: Cardiology Source Type: research

Ticagrelor or Prasugrel in Patients with ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
Conclusions: In patients with STEMI undergoing primary PCI, there was no significant difference in the primary endpoint between prasugrel and ticagrelor. Ticagrelor was associated with a significant increase in the risk for recurrent myocardial infarction. Clinical Trial Registration: URL: https://www.clinicaltrials.gov; Unique identifier NCT01944800. PMID: 33115278 [PubMed - as supplied by publisher]
Source: Circulation - October 29, 2020 Category: Cardiology Authors: Aytekin A, Ndrepepa G, Neumann FJ, Menichelli M, Mayer K, Wöhrle J, Bernlochner I, Lahu S, Richardt G, Witzenbichler B, Sibbing D, Cassese S, Angiolillo DJ, Valina C, Kufner S, Liebetrau C, Hamm CW, Xhepa E, Hapfelmeier A, Sager HB, Wustrow I, Joner M, T Tags: Circulation Source Type: research

Incidence and Clinical Impact of Major Bleeding Following Left Atrial Appendage Occlusion: Insights from the Amplatzer ™ Amulet™ LAA Occluder Observational Study.
CONCLUSIONS: In real-world patients at high bleeding risk, MB following LAAO was not uncommon and associated with a significant increase in mortality, without increasing the risk of stroke. PMID: 33495144 [PubMed - as supplied by publisher]
Source: EuroIntervention - January 27, 2021 Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research

Association Between Atrial High-Rate Episodes and Ischemic/Major Bleeding Events in Patients With a Cardiac Implantable Electronic Device 　- A 10-Year, Single-Center Historical Cohort Study
CONCLUSIONS: Longer AHRE duration is associated with a high number of major bleeding and ischemic events. Monitoring these bleeding risks is mandatory when clinicians are considering anticoagulation therapy for such patients.PMID:33867407 | DOI:10.1253/circj.CJ-20-1269
Source: Circulation Journal - April 19, 2021 Category: Cardiology Authors: Hironori Ishiguchi Akihiko Shimizu Masahiro Ishikura Masaaki Yoshida Koji Imoto Kazuhiko Sonoyama Tetsuya Kawabata Takashi Sugamori Masaya Ogawa Tomoyuki Uchida Tsukasa Nakamura Takeshi Morimoto Yu Yasuda Kazuaki Tanabe Yasuhiro Yoshiga Takayuki Okamura S Source Type: research